乌兹别克斯坦儿童慢性乙型肝炎病毒感染患病率:疫苗接种的影响
乌兹别克斯坦2001年引入婴儿乙型肝炎疫苗接种,2022年开展全国学龄儿童血清学调查。全国HBsAg患病率为0.20%(调整95%CI 0.09%-0.38%),已达成欧洲区域<0.5%的控制目标,并基于≥90%的HepB-BD和HepB3覆盖率于2023年获区域认证。
要点
- 全国儿童HBsAg患病率为0.20%(95%CI 0.09%-0.38%),达到欧洲区域<0.5%目标。
- 97.7%儿童接种≥3剂HepB,94.9%接种出生剂量,其中93.7%为及时接种。
- 2023年乌兹别克斯坦获认证达成区域乙型肝炎控制目标,但消除母婴传播仍需额外干预。
核心结论
- 调查显示乌兹别克斯坦已达到欧洲区域HBsAg血清患病率<0.5%的控制目标,并在实现乙型肝炎母婴传播消除的<0.1%目标方面取得实质性进展。
- 基于这些发现及≥90%的HepB-BD和HepB3覆盖率,乌兹别克斯坦于2023年获认证达成区域乙型肝炎控制目标。
- 为实现乙型肝炎母婴传播消除,应考虑额外干预措施,包括改善产前HBsAg筛查、为符合条件的HBsAg阳性孕妇提供抗病毒治疗以及为HBsAg阳性母亲所生婴儿提供乙型肝炎免疫球蛋白。
研究设计与样本
- 2022年开展全国性学龄儿童(1-3年级)血清学调查,采用分层多阶段整群设计。
- 共在148所学校招募4119名儿童,其中3753名(91.1%)采集血标本,3833名(93.3%)有免疫接种数据。
- 血标本采用WHO预认证快速检测(Bioline HBsAg WB,Abbott Diagnostics)检测HBsAg,阳性和不确定结果采用ELISA(Murex HBsAg Version3,Diasorine)复检。
主要发现
- 全国HBsAg患病率为0.20%(调整95%CI 0.09%-0.38%)。
- 在有免疫接种数据的儿童中,97.7%(95%CI 97.2%-98.1%)接种≥3剂HepB,94.9%(95%CI 94.1%-95.5%)接种HepB出生剂量,其中及时接种HepB出生剂量者为93.7%(95%CI 92.9%-94.5%)。
关键数值与推荐
- 欧洲区域HBsAg血清患病率控制目标为<0.5%,乌兹别克斯坦全国儿童患病率0.20%(95%CI 0.09%-0.38%)达到该目标。
- 乙型肝炎母婴传播消除的HBsAg血清患病率目标为<0.1%,调查显示已取得实质性进展。
- 区域乙型肝炎控制目标认证条件包括HepB出生剂量和HepB3覆盖率≥90%,乌兹别克斯坦二者覆盖率分别为94.9%和97.7%。
临床怎么用
- 作者认为,为实现乙型肝炎母婴传播消除,应考虑额外干预措施,包括改善产前HBsAg筛查、为符合条件的HBsAg阳性孕妇提供抗病毒治疗以及为HBsAg阳性母亲所生婴儿提供乙型肝炎免疫球蛋白。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uzbekistan, a highly endemic country for hepatitis B virus (HBV), introduced infant vaccination with hepatitis B vaccine (HepB) in 2001. Since 2002, it had ≥90 % reported immunization coverage for ≥3 doses of HepB (HepB3) and the birth dose (HepB-BD). However, the impact of HepB vaccination and the progress towards achieving the regional hepatitis B control and global viral hepatitis B elimination goals had not been assessed. METHODS: To determine current HBsAg prevalence among children in Uzbekistan, in 2022, we conducted a nationwide serosurvey among schoolchildren (grades 1-3) using a stratified, multi-stage cluster design. Participants' basic demographics and HepB immunization information were obtained. Blood specimens were tested for HBsAg using a WHO-prequalified rapid test (Bioline HBsAg WB, Abbott Diagnostics). Samples with positive and indeterminate results were tested for HBsAg by ELISA (Murex HBsAg Version3, Diasorine). Weighted proportions and adjusted 95 % confidence intervals (CI) were calculated. RESULTS: Of 4119 children enrolled in 148 schools, blood was collected from 3753 (91.1 %) and immunization data were available for 3833 (93.3 %). National HBsAg prevalence was 0.20 % (adjusted 95 % CI, 0.09 %-0.38 %). Among children with available immunization data, 97.7 % (97.2 %-98.1 %) received ≥3 HepB doses and 94.9 % (94.1 %-95.5 %) received HepB-BD, including timely HepB-BD in 93.7 % (92.9 %-94.5 %). CONCLUSIONS: The survey demonstrated that Uzbekistan has met the <0.5 % European regional HBsAg seroprevalence target and has made substantial progress towards meeting the <0.1 % HBsAg seroprevalence target for the elimination of HBV mother to-child transmission (MTCT). Based on these findings and ≥ 90 % HepB-BD and HepB3 coverage, in 2023, Uzbekistan was validated as having achieved the regional hepatitis B control goal. To achieve the elimination of MTCT of HBV, additional interventions, including improving antenatal screening for HBsAg, providing antiviral treatment of eligible HBsAg-positive pregnant women and hepatitis B immunoglobulin to infants born to HBsAg-positive mothers, should be considered.
引用
- Khetsuriani N, Tursunova D, Kasimova R, et al. Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination. Vaccine. 2025. PMID: 39862544. doi:10.1016/j.vaccine.2025.126743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。